SOPHiA GENETICS (NASDAQ: SOPH) lifts 2025 revenue, names new CEO

Rhea-AI Filing Summary

SOPHiA GENETICS SA reported a leadership change and strong preliminary 2025 results. The company promoted Ross Muken, currently President and a key executive for five years, to Chief Executive Officer effective July 1, 2026. He is expected to succeed co‑founder Dr. Jurgi Camblong, who will move to Executive Chairman of the Board, subject to election at the Annual General Meeting in June 2026.

For the quarter ended December 31, 2025, the company expects revenue of at least $21 million, about a 20% year‑over‑year increase, and more than 105,000 analyses on SOPHiA DDM, up 16% year‑over‑year. For the full year 2025, it expects revenue of about $77 million, an 18% year‑over‑year increase, and over 391,000 analyses, which it calls a company record. These figures are preliminary, unaudited estimates and may change as year‑end closing and audit work are completed, and the company’s independent auditors have not expressed an opinion on them.

Positive

• Strong preliminary 2025 growth: Q4 revenue of at least $21 million and full‑year about $77 million, with double‑digit year‑over‑year increases in both revenue and SOPHiA DDM analyses, including a record 391,000 analyses for the year.

Negative

• None.

Insights

Equity analyst – software and data platforms

Double‑digit 2025 growth and a planned CEO transition, based on preliminary figures.

The company anticipates solid top‑line expansion, with Q4 2025 revenue of at least $21 million, roughly a 20% year‑over‑year increase, and full‑year 2025 revenue of about $77 million, up around 18%. Activity on the SOPHiA DDM platform also rose, with over 105,000 analyses in Q4 (up 16% year‑over‑year) and more than 391,000 for the year, which is described as a company record. This suggests both commercial and usage momentum through the end of 2025.

Governance is evolving as President Ross Muken is set to become CEO effective July 1, 2026, while co‑founder Dr. Jurgi Camblong is expected to assume the Executive Chairman role, subject to shareholder election at the Annual General Meeting in June 2026. The company stresses that these financial figures are preliminary and unaudited; it is still completing year‑end close procedures, and its independent auditors have not opined on the estimates, so final reported results could differ.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026.

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in its charter)

La Pièce 12

CH-1180 Rolle

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

On January 12, 2026, SOPHiA GENETICS SA (the “Company”) announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a key executive at the company for five years, will succeed Dr. Jurgi Camblong, co-founder and CEO. Dr. Camblong will transition to Executive Chairman of the Board, subject to election at the Company’s Annual General Meeting in June 2026.

In addition, the Company announced certain preliminary unaudited financial results for the quarter and the year ended December 31, 2025. For the quarter ended December 31, 2025, the Company expects to report revenue of at least $21 million, representing an increase of approximately 20% year-over-year, and the Company performed over 105,000 analyses on SOPHiA DDM, representing 16% year-over-year growth. For the year ended December 31, 2025, the Company expects to report revenue of approximately $77 million, representing an increase of approximately 18% year-over-year, and the Company performed over 391,000 analyses on SOPHiA DDM, a new company record. The Company has not completed preparation of its financial statements for the quarter and the year ended December 31, 2025. The estimates presented in this Form 6-K for the quarter and year ended December 31, 2025 are preliminary and unaudited and are thus inherently uncertain and subject to change as the Company completes its financial results for the fourth quarter of 2025. The Company is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the course of the preparation of the Company’s consolidated financial statements and related notes as of and for the year ended December 31, 2025, the Company may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein. The Company’s independent registered public accountants do not express any opinion regarding the preliminary financial estimates presented herein.

INCORPORATION BY REFERENCE

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-280060, 333-289266 and 333-289270) of SOPHiA GENETICS SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SOPHiA GENETICS SA
Date: January 12, 2026
	By:	/s/ Daan van Well
	Name:	Daan van Well
	Title:	Chief Legal and Regulatory Officer

FAQ

What leadership changes did SOPHiA GENETICS (SOPH) announce?

SOPHiA GENETICS announced that Ross Muken, currently President, will become Chief Executive Officer effective July 1, 2026. He will succeed co‑founder Dr. Jurgi Camblong, who is expected to transition to Executive Chairman of the Board, subject to his election at the Annual General Meeting in June 2026.

What are SOPHiA GENETICS’ preliminary Q4 2025 revenue results?

For the quarter ended December 31, 2025, SOPHiA GENETICS expects to report revenue of at least $21 million, which it states represents an increase of approximately 20% year‑over‑year.

How did SOPHiA GENETICS’ SOPHiA DDM usage trend in Q4 2025?

In Q4 2025, the company performed over 105,000 analyses on SOPHiA DDM, representing 16% year‑over‑year growth, indicating higher platform usage compared with the prior‑year quarter.

What are the preliminary full‑year 2025 results for SOPHiA GENETICS?

For the year ended December 31, 2025, SOPHiA GENETICS expects to report revenue of approximately $77 million, an increase of about 18% year‑over‑year, and more than 391,000 analyses on SOPHiA DDM, which the company describes as a new record.

Are SOPHiA GENETICS’ 2025 financial figures final and audited?

No. The company states that the 2025 quarterly and full‑year figures are preliminary and unaudited, prepared during its customary year‑end close process. It notes that final reported results may differ and that its independent registered public accountants do not express any opinion on these preliminary estimates.

How is this Form 6-K used in SOPHiA GENETICS’ registration statements?

The company states that this Form 6‑K is deemed incorporated by reference into its registration statements on Form F‑3 with Registration Nos. 333‑280060, 333‑289266 and 333‑289270, becoming part of those documents from the filing date unless later superseded.